Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs
Open Access
- 11 March 2022
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (3) , e0264909
Abstract
Evidence for beneficial effects of corticotropin releasing hormone (CRH) antagonists in abdominal and pelvic organs is emerging in preclinical studies. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement a compilation of preclinical studies using CRH receptor antagonists as a treatment for abdominal and pelvic disease was carried out. The Animal Research: Reporting of In Vivo Experiments (ARRIVE) essential 10 guidelines were used to determine quality of the included studies. A total of 40 studies from the last 15 years studying irritable bowel syndrome, inflammatory bowel disease, endometriosis, enteritis, stress impact on gastrointestinal processes and exogenous CRH administration effects were included. Blockage of the CRH receptor 1 was mainly associated with beneficial effects while that of CRH receptor 2 worsened studied effects. However, time of administration, route of administration and the animal model used, all had an impact on the beneficial outcomes. Frequency of drugs administered indicated that astressin-2B, astressin and antalarmin were among the most utilized antagonists. Of concern, studies included were predominantly carried out in male models only, representing a gender discrepancy in preclinical studies compared to the clinical scenario. The ARRIVE score average was 13 with ~60% of the studies failing to randomize or blind the experimental units. Despite the failure to date of the CRH antagonists in moving across the clinical trials pipeline, there is evidence for their beneficial effects beyond mood disorders. Future pre-clinical studies should be tailored towards effectively predicting the clinical scenario, including reduction of bias and randomization.Keywords
Funding Information
- National Institute of General Medical Sciences (GM082406)
This publication has 74 references indexed in Scilit:
- The Newly Developed CRF1-Receptor Antagonists, NGD 98-2 and NGD 9002, Suppress Acute Stress-Induced Stimulation of Colonic Motor Function and Visceral Hypersensitivity in RatsPLOS ONE, 2013
- Corticotropin-Releasing Factor Receptor 1 Antagonist Alters Regional Activation and Effective Connectivity in an Emotional–Arousal Circuit during Expectation of Abdominal PainJournal of Neuroscience, 2011
- Transient Gastric Irritation in the Neonatal Rats Leads to Changes in Hypothalamic CRF Expression, Depression- and Anxiety-Like Behavior as AdultsPLOS ONE, 2011
- Activation of Corticotropin-Releasing Factor Receptor 2 Mediates the Colonic Motor Coping Response to Acute Stress in RodentsGastroenterology, 2011
- Corticotropin-Releasing Hormone Family of Peptides Regulates Intestinal AngiogenesisGastroenterology, 2010
- Cortagine, a CRF1agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathwaysAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?American Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- Cholinergic giant migrating contractions in conscious mouse colon assessed by using a novel noninvasive solid-state manometry method: modulation by stressorsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- Footshock-Induced Urinary Bladder Hypersensitivity: Role of Spinal Corticotropin-Releasing Factor ReceptorsThe Journal of Pain, 2008
- Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin‐releasing factor and nerve growth factor interplayThe Journal of Physiology, 2007